From next year production for the Moderna vaccine in Visp is to be doubled. But this time, too, the Confederation gave Lonza a rejection.
—
–Lonza employees in Visp: Three streets for the active ingredient production of the Covid-19 vaccine already exist, now the capacity is to be doubled.
Photo: Keystone
The announcement came early on Thursday morning – and was surprising. The companies Moderna and Lonza announced that their vaccine production capacity in Visp VS is to be doubled. In addition to the three existing production lines, another three will be added from the beginning of 2022. Each with a capacity of 100 million cans per year.
Both partners are silent about how high the investment in Visp will be. Lonza also left unanswered the question of whether Switzerland will participate financially in vaccine production in the second attempt: “You have to ask the Swiss government this question,” said a Lonza spokeswoman when asked.
